Neurotransmitter Or Derivative Affecting Or Utilizing Patents (Class 514/18.1)
-
Patent number: 11684579Abstract: A multivesicular liposome composition includes a plurality of multivesicular liposomes. Each multivesicular liposome includes a carrier liposome particle including carrier phospholipid bilayer and having an average diameter less than 1 micron; and at least one sub-chamber liposome nanoparticle including a sub-chamber liposome nanoparticle bilayer and having an average diameter less than about 50 nm. The carrier liposome particle encapsulates the at least one sub-chamber liposome nanoparticle. Characteristically, tail groups of the carrier liposome phospholipids are larger than tail groups phospholipids of the at least one sub-chamber liposome nanoparticle.Type: GrantFiled: April 29, 2019Date of Patent: June 27, 2023Assignee: KARMA BIOTECHNOLOGIESInventors: Andrew Brovko Gray, Donald Dewane Johnson, Alan Michael Johnson
-
Patent number: 11279744Abstract: The present invention relates to a novel peptide exhibiting an effect of releasing myelopoiesis stem cells into blood and an osteoporosis therapeutic effect and use thereof and, in particularly, to a novel peptide consisting of an amino acid sequence of SEQ. ID.NO:1 which has effects of releasing hematopoietic stem cells into a bloodstream and decreasing osteoclast cells in bone narrow, and a pharmaceutical composition comprising the novel peptide as an active ingredient for preventing or treating neutropenia, anemia or osteoporosis. Because of side effects, the peptide of the present invention not only increases level of leukocytes, red blood cells and platelets in blood, but also alleviates a decrease in bone density, and therefore, can be very usefully used for the development of a prophylactic or therapeutic agent for neutropenia, anemia or osteoporosis.Type: GrantFiled: January 3, 2020Date of Patent: March 22, 2022Assignee: Kyungpook National University Industry-Academic Cooperation FoundationInventors: Jae Sung Bae, Hee Kyung Jin, Min Hee Park
-
Patent number: 10605812Abstract: A method for predicting the risk of getting cancer in a subject that does not suffer from cancer or alternatively diagnosing cancer in a subject, where the method includes determining the level of Pro-Tachykinin, its splice variants or fragments thereof of at least 5 amino acids, where the fragments including Substance P and Neurokinin, in a bodily fluid obtained from the subject; and correlating the level of Pro-Tachykinin, its splice variants or fragments thereof with a risk for getting cancer, wherein a reduced Pro-Tachykinin level is predictive for an enhanced risk of getting cancer or alternatively diagnosing cancer wherein a reduced level is correlated with the diagnosis of cancer.Type: GrantFiled: January 7, 2014Date of Patent: March 31, 2020Assignee: SphingoTec GmbHInventor: Andreas Bergmann
-
Publication number: 20150140015Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of pancreatic cancers. In particular, the present invention relates to an OX1R agonist for use in the treatment of pancreatic cancer in a subject in need thereof.Type: ApplicationFiled: January 20, 2015Publication date: May 21, 2015Inventor: Thierry VOISON
-
Patent number: 8986690Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.Type: GrantFiled: May 27, 2011Date of Patent: March 24, 2015Assignee: H. Lundbeck A/SInventors: Anders Nykjaer, Claus Munck Petersen
-
Publication number: 20150057231Abstract: The invention relates to the use of an Engrailed protein as a medicament for increasing dopamine synthesis by dopaminergic neurons, in particular in the management of conditions associated with a decrease of dopamine levels without loss of dopaminergic neuronsType: ApplicationFiled: February 29, 2012Publication date: February 26, 2015Applicants: COLLEGE DE FRANCE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Alain Prochiantz, Kenneth Moya, Rajiv Joshi
-
Publication number: 20150050289Abstract: Agents, compositions, and medicaments that pertain to modulating the activity of muscle specific kinase receptor (MuSK) and methods and uses thereof to modulate MuSK activity are encompassed herein. Also encompassed are screening assays to identify modulators of MuSK activity. Agents identified using the screening assays described herein are envisioned for use as therapeutics, alone or in compositions or in medicaments, to alleviate or delay motor dysfunction in subjects afflicted with a disorder associated with nerve terminal loss or fragmentation, such as amyotrophic lateral sclerosis, sarcopenia, or anti-MuSK myasthenia gravis.Type: ApplicationFiled: November 14, 2012Publication date: February 19, 2015Inventor: Steven J. Burden
-
Patent number: 8945623Abstract: The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.Type: GrantFiled: May 3, 2006Date of Patent: February 3, 2015Assignee: Warsaw Orthopedic, Inc.Inventors: Josee Roy, William F. McKay, Jeffrey C. Marx
-
Patent number: 8911731Abstract: The present invention provides monoclonal antibodies which specifically recognize the shorter A? peptides obtained after cleavage of the APP protein mediated by ?-secretase, i.e. the A?-peptide fragments A?1-37, A?3-37, A?3p-37, A?1-37 and A?11p-37, and other like fragments ending at the 37th amino acid of APP, hereinafter also referred to as the A?x-37 peptides. It further provides hybridoma cells producing the monoclonal antibodies as well as methods for producing the antibodies and the hybridoma cells; and an immunoassay for an A?x-37 peptide by a competitive method or a sandwich method using the antibody of the present invention; and methods for measuring the level of A?x-37 peptides in a sample, such as a biological sample.Type: GrantFiled: July 6, 2012Date of Patent: December 16, 2014Assignee: Janssen Pharmaceutica NVInventors: Marc Hubert Mercken, Marianne Borgers, Marc Maria Pierre Pelagie Vandermeeren, Bianca Julia J Van Broeck
-
Publication number: 20140290647Abstract: The invention concerns a product consisting of distilled water or of an aqueous solution hypotonic or substantially isotonic with respect to blood plasma or, less preferably, hypertonic with respect to blood plasma, to be administered on the nasal mucosa according to a specific operation mode in order to cause an inflammation of an irritative kind, for use in a treatment of stimulation of the endogenous production of inflammatory mediators, in the therapy and prevention of neurological disorders, in particular of degenerative disorders of the central and peripheral nervous system. The inflammatory mediators the endogenous production of which is stimulated comprise NGF, neurotrophin-3, neurotrophin-4, serotonin, substance P, heparin, ECF-A.Type: ApplicationFiled: July 20, 2012Publication date: October 2, 2014Inventors: Fabrizio Salvinelli, Beatrice Salvinelli, Emanuele Salvinelli, Alessandra d'Eramo
-
Publication number: 20140286885Abstract: The present disclosure is directed to peptide-based compounds, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present disclosure may inhibit neurotransmitter release and muscle contraction as a treatment for wrinkles. The compounds of the disclosure may be used for pathological neuronal exocytosis-mediated cosmetic and/or therapeutic purposes.Type: ApplicationFiled: November 7, 2012Publication date: September 25, 2014Inventors: Feng Tian, Daniel Liang Zou, Lingyun Ji
-
Publication number: 20140249090Abstract: The present invention provides peptides for use in a medicament which is administered nasally, wherein the peptide is an agonist of neuropeptide S receptor (NPSR), of the receptor TGR23 and/or of vasopressin receptor-related receptor 1 (VRR1) or for use in the treatment of a patient by causing, promoting or increasing relieve or healing of phobic anxiety, avoidance anxiety, dissociative anxiety such as flashbacks, depersonalization, derealization, intrusions, vegetative symptoms related to anxiety symptoms, especially in panic attacks, in posttraumatic stress disorder, in generalised anxiety disorder and in anxiety accompanying depressive, or psychotic episodes, arousal, awakening, alertness, activity, spontaneous movement, an anxiolytic effect or a combination thereof in the patient, wherein the peptide is administered nasally or for use in the prophylaxis and/or treatment of an anxiety or sleep disorder, especially in any type of hypersomnia like idiopathic hypersomnia, wherein the peptide is administered nType: ApplicationFiled: April 2, 2012Publication date: September 4, 2014Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FĂ–RDERUNG DER WISSENSCHAFT E.V.Inventors: Yi-Chun Yen, Axel Steiger, Florian Holsboer, Rainer Landgraf, Irina Alexandra Ionescu, Ulrike Schmidt
-
Patent number: 8796216Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumor cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalized and inhibits secretion from said tumor cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.Type: GrantFiled: December 16, 2010Date of Patent: August 5, 2014Assignee: Syntaxin LimitedInventors: Stephen Johnstone, Philip Marks, Keith Foster
-
Publication number: 20140213523Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include Amyotrophic Lateral Sclerosis (ALS), as well as muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: ApplicationFiled: October 9, 2013Publication date: July 31, 2014Applicant: Tivorsan Pharmaceuticals, Inc.Inventors: Justin Fallon, Elizabeth John
-
Publication number: 20140170162Abstract: The invention relates to treatment and/or prevention of nerve injury. In one embodiment, the present invention provides a method of preserving the neuromuscular junction (NMJ) in an individual by administering a therapeutically effective dosage of a composition comprising an inhibitor of Wnt3a, and an inhibitor of MMP3 to the individual. In another embodiment, the present invention provides a method of stabilizing NMJ after nerve injury by inhibiting the WNT and beta-catenin signaling pathway and preserving agrin.Type: ApplicationFiled: December 18, 2013Publication date: June 19, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Ranjan Gupta
-
Patent number: 8754034Abstract: The invention provides methods for designing peptides that inhibit aggregation in target polypeptides. The candidate inhibitory peptidic compounds have an oligomeric sequence that forms energetically-favorable interactions with the amino acid sequence of the steric zipper region of the target protein, and also possess a zipper-disrupting feature that disrupt the peptide stacking at the steric zipper region. This method can be used to obtain inhibitory peptides to disrupt fibril formation involving any protein for which a steric zipper sequence can be identified. The invention also provides inhibitory peptidic compounds, which can be used in pharmaceutical compositions and methods for treating polypeptide aggregation-associated diseases or conditions.Type: GrantFiled: February 8, 2010Date of Patent: June 17, 2014Assignees: The Regents of the University of California, University of WashingtonInventors: David S. Eisenberg, Stuart A. Sievers, John Karanicolas, David Baker
-
Patent number: 8748578Abstract: The invention relates to mutant channelrhodopsins having improved properties, nucleic acid constructs encoding same, expression vectors carrying the nucleic acid construct, cells comprising said nucleic acid construct or expression vector, and their respective uses.Type: GrantFiled: September 8, 2011Date of Patent: June 10, 2014Assignee: Max-Planck-Gesellschaft zur Foerderrung der Wissenschaften e.V.Inventors: Ernst Bamberg, Christian Bamann, Sonja Kleinlogel, Phillip Wood, Robert E. Dempski
-
Publication number: 20140148393Abstract: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.Type: ApplicationFiled: January 13, 2014Publication date: May 29, 2014Applicant: University of Kentucky Research FoundationInventors: Luke BRADLEY, Don Marshall GASH, Greg GERHARDT
-
Patent number: 8735541Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: GrantFiled: June 6, 2013Date of Patent: May 27, 2014Assignee: The University of Utah Research FoundationInventors: Maren Watkins, Baldomero M. Olivera, David R. Hillyard, J. Michael McIntosh
-
Patent number: 8691766Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: GrantFiled: February 8, 2012Date of Patent: April 8, 2014Assignee: Brown University Research FoundationInventors: Justin R. Fallon, Beth A. McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison R. Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Publication number: 20140094415Abstract: The invention provides novel potent inhibitors of the ternary protein complex of nNOS, PSD-95, and the NMDA receptor and pharmaceutical compositions comprising the inhibitors for prophylaxis and/or treatment of excitotoxic-related disease and chronic pain conditions in a subject. The inhibitors are dimeric PSD-95 inhibitors comprising a first peptide or peptide analogue linked to a second peptide or peptide analogue by a linker, wherein the first and the second peptide or peptide analogue comprise at least four amide-bonded residues having a sequence YTXV or YSXV, wherein a. Y is selected from among E, Q, and A, or an analogue thereof, and b. X is selected from among A, Q, D, N,N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, and wherein a Cell Penetrating Peptide (CPP) is linked to the linker or to an amino acid side chain of the first and second peptide or peptide analogue. The linker can be a PEG or NPEG linker.Type: ApplicationFiled: May 11, 2012Publication date: April 3, 2014Inventors: Anders Bach, Kristian Stromgaard
-
Publication number: 20140065109Abstract: The present invention relates to a use of Substance-P for the manufacture of a medicament for mobilization or proliferation of Mesenchymal stem cells (MSCs) from the bone marrow, or facilitating said mobilization or proliferation, and use of Substance-P for the manufacture of a medicament for wound-healing or facilitating wound-healing.Type: ApplicationFiled: September 5, 2013Publication date: March 6, 2014Applicants: Chung-Ang University Industry-Academy Cooperation Foundation, Korea Institute of Radiological & Medical SciencesInventors: Young Sook Son, Hyun Sook Hong, Jae Chan Kim
-
Publication number: 20130345122Abstract: The present invention provides for diagnosis or treatment of neurological or neuropsychiatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for modulating dopamine transporter activity and modulating dopaminergic neurotransmission. Agents of the present invention include fragments of D2 receptor or dopamine transporter (DAT) that can disrupt D2-DAT coupling.Type: ApplicationFiled: August 14, 2013Publication date: December 26, 2013Applicant: Centre for Addiction and Mental HealthInventor: Fang LIU
-
Publication number: 20130323187Abstract: The present invention describes material and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation.Type: ApplicationFiled: November 26, 2012Publication date: December 5, 2013Applicant: PARTNERSHIP & CORP. TECHNOLOGY TRANSFERInventors: Nicolas Fasel, Amal Kuendig
-
Publication number: 20130261062Abstract: The present specification discloses the use of Targeted Exocytosis Modulators to the sphenopalatine ganglion to treat headache disorders.Type: ApplicationFiled: October 13, 2011Publication date: October 3, 2013Applicant: Allergan, Inc.Inventor: Andrew M. Blumenfeld
-
Patent number: 8541373Abstract: A method of attenuating a biological effect of cocaine exposure in a primate. Such method includes administering to the primate an amount of a BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G, wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of cocaine exposure in the primate.Type: GrantFiled: December 7, 2010Date of Patent: September 24, 2013Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Liora Sklair-Tavron, Moti Rosenstock, Liron Shemesh-Darvish, Hussein Hallak, Victor Piryatinsky, Viktor Roschke, David Lafleur
-
Publication number: 20130236497Abstract: The present invention provides a method of treating a cancer using a neurotoxin, preferably Botulinum toxin (“BTX”). The application of a neurotoxin around a cancer acts to decrease the contractile forces of the muscles surrounding a neoplasm which normally squeeze cancer cells through efferent channels leaving the cancer vicinity to distant sites. Also, the application of the toxin at sites distant from the cancer enhances cellular and humoral immunologic functions which further contributes to cancer cell death and spread. Following administration of botulinum toxin around and distant to a cancer, it is noticed that local, regional, and distant spread is reduced or eliminated. Immunomodulation with botulinum toxin is also valuable in treating other disease that may or may not be associated with cancers, such as viral-induced growths, viral conditions, fungal disease, chronic wounds, graft versus host disease, autoimmune disease, and HIV.Type: ApplicationFiled: May 2, 2013Publication date: September 12, 2013Applicant: TOXCURE, LLCInventor: Christopher Shaari
-
Publication number: 20130202600Abstract: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.Type: ApplicationFiled: April 12, 2013Publication date: August 8, 2013Applicant: Centre for Addiction and Mental HealthInventor: Centre for Addiction and Mental Health
-
Patent number: 8487075Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: GrantFiled: February 7, 2012Date of Patent: July 16, 2013Assignee: The University of Utah Research FoundationInventors: Maren Watkins, Baldomero M. Olivera, David R. Hillyard, J. Michael McIntosh, Robert M. Jones
-
Patent number: 8470546Abstract: Methods are provided for treating autism spectrum disorders (ASD) using agents that activate the locus coeruleus-noradrenergic (LC-NA) system of the brain and for screening for compounds for treating ASD comprising determining whether or not the compounds activate the LC-NA system.Type: GrantFiled: October 29, 2009Date of Patent: June 25, 2013Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Dominick P. Purpura, Mark F. Mehler
-
Patent number: 8470779Abstract: A novel mammalian catecholamine-regulated protein called CRP40 is identified. This protein, and nucleic acid encoding same, is useful in methods of diagnosing and treating hypodopaminergic neurological disease, such as Parkinson's disease, multisystem atrophy, lewy body dementia, schizophrenia, and bipolar disease.Type: GrantFiled: March 7, 2011Date of Patent: June 25, 2013Assignee: CRP40 Inc.Inventors: Joseph Gabriele, Ram Mishra, Zdenek Pristupa
-
Patent number: 8420105Abstract: Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.Type: GrantFiled: August 18, 2011Date of Patent: April 16, 2013Assignee: Allergan, Inc.Inventor: Patricia S. Walker
-
Patent number: 8420775Abstract: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.Type: GrantFiled: June 12, 2009Date of Patent: April 16, 2013Assignee: Centre for Addiction and Mental HealthInventor: Fang Liu
-
Publication number: 20130071412Abstract: The invention features a powdered composition including a pharmaceutically active compound and a protein or a hydrolyzed protein. In particular, the powdered composition forms a stable solution or dispersion suitable for oral administration in which the protein or the hydrolyzed protein is bound to the pharmaceutically active compound. The invention also provides a method of administering the composition, such as to a patient with dysphasia; liquid or semi-solid formulations of the composition; methods for preparing the composition; and kits including the composition.Type: ApplicationFiled: December 17, 2010Publication date: March 21, 2013Applicant: Exodos Life Sciences Limited PartnershipInventors: Harry J. Leighton, Crist J. Frangakis
-
Publication number: 20130072437Abstract: The present invention relates to new therapeutic and diagnostic uses of soluble neuregulin-1 isoforms and polypeptides, particularly neurological disorders.Type: ApplicationFiled: May 27, 2011Publication date: March 21, 2013Applicant: MIND-NRG SAInventors: Thierry Baussant, Daniel Bach, André Schrattenholz
-
Publication number: 20130059789Abstract: Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided.Type: ApplicationFiled: October 18, 2012Publication date: March 7, 2013Applicant: ALLERGAN, INC.Inventor: Allergan, Inc.
-
Publication number: 20130035293Abstract: The present invention provides for diagnosis or treatment of neurological or neuropsychiatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for modulating dopamine transporter activity and modulating dopaminergic neurotransmission. Agents of the present invention include fragments of D2 receptor or dopamine transporter (DAT) that can disrupt D2-DAT coupling.Type: ApplicationFiled: October 5, 2012Publication date: February 7, 2013Applicant: CENTRE FOR ADDICTION AND MENTAL HEALTHInventor: CENTRE FOR ADDICTION AND MENTAL HEALT
-
Patent number: 8367610Abstract: A method for administering nerve growth factor to treat cravings is provided. Pharmaceutical compositions for the treatment of cravings comprising nerve growth factor are also provided.Type: GrantFiled: October 5, 2009Date of Patent: February 5, 2013Assignee: Beech Tree Labs, Inc.Inventor: John McMichael
-
Patent number: 8343927Abstract: The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.Type: GrantFiled: September 13, 2010Date of Patent: January 1, 2013Assignee: Shire LLCInventors: Travis Mickle, Suma Krishnan, James Scott Moncrief, Christopher Lauderback
-
Patent number: 8334263Abstract: Compositions of flupirtine for management of neuropathic or inflammatory pain optionally including one or more other analgesics including opiates, NSAIDS and other active agents in immediate and controlled release forms. Methods and systems for administration of these compositions.Type: GrantFiled: December 16, 2004Date of Patent: December 18, 2012Inventors: Raymond Nadeson, Adam Paul Tucker, Colin Goodchild
-
Publication number: 20120302507Abstract: Disclosed are a liquid product of botulinum toxin type A and a method for conserving the potency of botulinum toxin type A using a dextrose solution. Free of a stabilizer, such as albumin or gelatin, the liquid product of botulinum toxin type A completely excludes the possibility of cross infections such as AIDS and bovine spongiform encephalopathy. In addition, botulinum toxin type A is preserved as a liquid product in combination with a dextrose solution and can be clinically used as is, without the aid of physiological saline. Therefore, the liquid product enjoys the advantage of being convenient for use and avoiding a decrease in the potency as occurs upon dilution with physiological saline. Serving as a natural preserving and stabilizing agent, the dextrose solution allows botulinum toxin type A to be stored and distributed in the form of liquid phase over a long period of time and conserves the potency of the toxin at a constant level, which in turn guarantees constant clinical results.Type: ApplicationFiled: April 20, 2012Publication date: November 29, 2012Inventor: Jong Wook HAM
-
Publication number: 20120283193Abstract: The present invention relates generally to methods, devices and compositions for treating mental, neurological, and cognitive diseases related to deficiencies in the biosynthesis and/or metabolism of neurotransmitters.Type: ApplicationFiled: October 29, 2010Publication date: November 8, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Nicholas C. Spitzer, Davide Dulcis
-
Patent number: 8278276Abstract: Subjects having autism are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen.Type: GrantFiled: January 31, 2012Date of Patent: October 2, 2012Assignee: Seaside Therapeutics, Inc.Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
-
Patent number: 8273715Abstract: Subjects having fragile X syndrome are treated with a composition that includes gamma-aminobutyric acid agonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen, including racemic and R-baclofen.Type: GrantFiled: January 31, 2012Date of Patent: September 25, 2012Assignee: Seaside Therapeutics, Inc.Inventors: Kathryn Roberts, Randall L. Carpenter, Mark F. Bear
-
Publication number: 20120238504Abstract: The invention includes liquid formulations of botulinum toxin, including hydrogel formulations that are stable to storage in liquid form at standard refrigerator temperatures for at least 1-2 years and to storage at higher temperatures for at least 6 months. The invention also includes methods of treatment using such formulations for various therapeutic and cosmetic purposes.Type: ApplicationFiled: April 5, 2012Publication date: September 20, 2012Applicant: SOLSTICE NEUROSCIENCES, LLCInventors: Elizabeth Moyer, Pamela Hirtzer, George A. Digenis, Ahmad H. Malkawi
-
Patent number: 8268784Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.Type: GrantFiled: August 6, 2009Date of Patent: September 18, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Karin Conde-Knape, Waleed Danho, George Ehrlich, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Rebecca Anne Taub, Jefferson Wright Tilley
-
Publication number: 20120225823Abstract: A method for increasing dopaminergic neurotransmission in a mammal in need of such treatment is provided. The method comprises disrupting Tat-DAT binding in the mammal.Type: ApplicationFiled: April 24, 2012Publication date: September 6, 2012Applicant: UNIVERSITY OF SOUTH CAROLINAInventors: Rosemarie M. Booze, Charles F. Mactutus, Jun Zhu
-
Publication number: 20120208751Abstract: The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to period between administrations of no greater than 1/2. The methods of the present invention may be used to address a whole host of undesirable mental, neurological and physiological conditions.Type: ApplicationFiled: April 20, 2012Publication date: August 16, 2012Inventor: Alexander Michalow
-
Patent number: 8226940Abstract: The present invention provides a polypeptide therapeutic agent, useful in enzyme replacement therapy, with increased therapeutic benefits for the central nervous system. The invention provides a method of enhancing the effect of a polypeptide or protein on the central nervous system by the attachment of a short acidic amino acid sequence. Specifically the inventors disclose the attachment of a 4-15 acidic amino acid sequence to human ?-glucuronidase by construction of a fusion protein. This molecule is useful in the treatment of type VII mucopolysaccharidosis when administered to a patient.Type: GrantFiled: February 28, 2010Date of Patent: July 24, 2012Assignee: Saint Louis UniversityInventors: Shunji Tomatsu, Adriana Montano, Tatsuo Nishioka, Jeffrey H. Grubb, William S. Sly, Monica A. Gutierrez, Amelia Ortigoza Rodriguez, legal representative
-
Patent number: 8193245Abstract: The present invention relates to the pharmaceutical composition and health care food comprising oleic acid having neuroprotective activity. The oleic acid of the present invention has potent neuroprotective effect and recovery effect on neurological behavior. Therefore, it is useful as the therapeutics for the prevention or treatment of degenerative brain diseases in human or mammal.Type: GrantFiled: January 9, 2006Date of Patent: June 5, 2012Assignee: University-Industry Cooperation Group of Kyung Hee UniversityInventors: Hocheol Kim, Dae Hee Lee, Mi Yeong Kim, Young Min Boo, Ni Na Ha, Jin Hee Jung